A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

Inclusion Criteria:

• Are on stable incretin therapy at screening

• With persistent obesity or overweight defined as:

• ≥30 kg/m2 OR

• ≥27 kg/m2 with at least one existing obesity related complication at screening:

• hypertension

• dyslipidemia

• obstructive sleep apnea

• cardiovascular disease (for example, ischemic cardiovascular disease, NewYork Heart Association Functional Class I-III heart failure), or

• type 2 diabetes

• Have a stable body weight (<5% body weight change) at screening

Exclusion Criteria:

• Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis,or abdominoplasty allowed if performed >1 year before screening)

• Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 monthsprior to screening)

• Have type 1 diabetes

• Have taken any of the following antihyperglycemic medications within 90 days beforescreening:

• dipeptidyl peptidase-4 (DPP-4) inhibitors

• amylin analogs

• insulin

• Have had within 90 days prior to screening:

• heart attack

• stroke

• coronary artery revascularization

• unstable angina, or

• hospitalization due to congestive heart failure

• Have a history or diagnosis of New York Heart Association Functional ClassificationClass IV congestive heart failure